Table 3. Clinical profile of Type 2 Diabetes Cohort.
| Clinical Characteristic | Value |
|---|---|
| Mean hemoglobin A1C –% | 8.1 ± 2.1 |
| Hypertension | |
| Diagnosis of hypertension–% | 45.8 |
| Systolic BP, mean–mmHg | 121.8 ± 20.4 |
| Diastolic BP, mean–mmHg | 74.9 ± 10.2 |
| Body mass index | |
| Mean | 28.0 ± 5.0 |
| BMI ≥ 25 –% | 70.8 |
| BMI ≥ 30 –% | 30.8 |
| Diabetic nephropathy indicatorsa | |
| GFR 30–60 –% | 40.1 |
| GFR ≤ 30 –% | 3.5 |
| Proteinuria–% | 33.6 |
| On dialysis–% | 2.1 |
| Medication prescriptions–% | |
| Metformin | 85.9 |
| Sulfonylurea | 44.4 |
| Insulin NPH | 25.4 |
| Insulin regular | 2.8 |
| No insulin or oral anti-diabetic agent | 5.0 |
| ACE inhibitor | 43.7 |
| Number of diabetes-related encounters in last 12 months | |
| Median | 11.5 |
| Interquartile range | 8–15 |
BP, blood pressure; BMI, body mass index, GFR, glomerular filtration rate.
a GFR was estimated from clinical variables using the CKD-EPI equation.